Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility and Effects on Markers in Spinal Fluid in Persons With Early Alzheimer's Disease When Treated With Valaciclovir - Open Fas II Pilot Study (VALZ-Pilot)

NCT02997982 is registered in ClinicalTrials.gov with Hugo Lovheim as lead sponsor.

NCT NCT02997982
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02997982 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility and Effects on Markers in Spinal Fluid in Persons With Early Alzheimer's Disease When Treated With Valaciclovir - Open Fas II Pilot Study (VALZ-Pilot)
Lead sponsor
Hugo Lovheim
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2016
Completion date
March 4, 2020
Enrollment
33 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, herpes simplex, mild cognitive impairment